Subscribe
shutterstock_1878287359_mats_wiklund
Mats Wiklund / Shutterstock.com
22 July 2021GenericsRory O'Neill

AstraZeneca loses major generics appeal in India

The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent